ライフサイエンスコーパス: isoproterenol

1 r metoprolol and the beta-adrenergic agonist isoproterenol.

2 opic response to the beta-adrenergic agonist isoproterenol.

3 cruitment of arrestin to beta2AR relative to isoproterenol.

4 gher beat rate and contractility response to isoproterenol.

5 itoneally injected by saline, propranolol or isoproterenol.

6 ization, although it was reduced relative to isoproterenol.

7 B-transduced hES2-vCMs uniquely responded to isoproterenol.

8 f contraction or procontractile signaling by isoproterenol.

9 (2)AR) at four concentrations of the agonist isoproterenol.

10 ine and in additional 16 of 44 (36.4%) after isoproterenol.

11 gnature for all of the compounds relative to isoproterenol.

12 ls observed in vivo, cells were treated with isoproterenol.

13 in the absence or in the presence of 125 nM isoproterenol.

14 0.01) but a preserved heart-rate response to isoproterenol.

15 oncentrations of the beta-adrenergic agonist isoproterenol.

16 rdiac hypertrophy, we stressed the mice with isoproterenol.

17 ells pretreated with beta-adrenergic agonist isoproterenol.

18 left ventricular myocytes in the presence of isoproterenol.

19 thermia group had a higher force response to isoproterenol.

20 ed the cardiac beta1-AR signaling pathway to isoproterenol.

21 stimulation with the beta-adrenergic agonist isoproterenol.

22 gle high dose of the beta-adrenergic agonist isoproterenol.

23 hythmic induction during stress testing with isoproterenol.

24 of 100 Hz) or weak stimulation augmented by isoproterenol.

25 lowing deactivation, similar to perfusion of isoproterenol.

26 re-elevated with the beta-adrenergic agonist isoproterenol.

27 th dystrophic mothers showed mortality after isoproterenol.

28 omparable to that seen in WT VM treated with isoproterenol.

29 We found that beta-AR stimulation with isoproterenol (0.1 muM) decreased the mitochondrial redo

30 aticity) in the presence of the beta-agonist isoproterenol (0.1 mum; ISO), from 0% to 64% (P < 0.05).

31 o elevated extracellular Ca (2.7 mmol/L) and isoproterenol (0.25 mumol/L) to induce diastolic Ca wave

32 imulation (acetylcholine [0.1 micromol/L] or isoproterenol [0.01-0.1 micromol/L]) after termination o

33 fused for 5 minutes with the beta-AR agonist isoproterenol (1 micromol/L) or the blockers CGP+ICI (ba

34 Adrenergic stimulation by isoproterenol (1 muM) or forskolin (5 muM) increased the

35 incubated in primary culture and exposed to isoproterenol (1 mumol/L) or vehicle for 30 hours.

36 Acetylcholine (1 mumol/L), isoproterenol (1 mumol/L), high calcium ([Ca(2+)](o)=5.4

37 Bolus infusions of saline and isoproterenol (1 or 2 mug) were administered in a blinde

38 by the cAMP-elevating agonists, forskolin or isoproterenol (10 muM) and by the Ca(2+)-elevating agoni

39 rrent at nearly saturating concentrations of isoproterenol (100 nM) were also significantly reduced,

40 Beta-adrenergic stimulation (isoproterenol, 100 nmol L(-1) ) evoked I(SK) in VMs from

41 ng was performed with continuous infusion of isoproterenol (45 mug/min) for 3 minutes.

42 eas S1PR1 downregulation can be triggered by isoproterenol (a beta-adrenergic receptor agonist) treat

43 iety in response to intravenous infusions of isoproterenol, a beta-adrenergic agonist similar to adre

44 L2 is upregulated in mouse hearts exposed to isoproterenol, a beta-adrenergic agonist, and isoprotere

45 We used isoproterenol, a rapidly acting peripheral beta-adrenerg

46 eriences following bolus infusions of either isoproterenol, a rapidly acting peripheral beta-adrenerg

47 phosphorylation of ryanodine receptors under isoproterenol administration in Nod1(-/-)-PMI mice.

48 ac hypertrophy was induced in mice either by isoproterenol administration or by aortic constriction.

49 opranolol administration and increased after isoproterenol administration.

50 ical and secretory manifestations induced by isoproterenol administration.

51 icular arrhythmias and lower mortality after isoproterenol administration.

52 Further, we show that orally administered DL-isoproterenol, an adrenergic receptor agonist whose skel

53 cidence of early afterdepolarizations during isoproterenol; an effect paralleled by reduced magnitude

54 otein-ligand interactions for two compounds, Isoproterenol and 5-fluorouridine, highlighted as supero

55 ice also showed reduced inotropic effects of isoproterenol and a reduced tendency for arrhythmias fol

56 Pacemaking was potentiated by isoproterenol and abolished with carbachol and AVRs had

57 ion but did not prevent subsequent rescue by isoproterenol and additional isoproterenol-mediated dese

58 as been shown to slow SANC rate responses to isoproterenol and decrease SR Ca(2+) content.

59 The combination of isoproterenol and fMRI offers a powerful approach for ev

60 2+) channels were appropriately regulated by isoproterenol and forskolin.

61 ss given by beta-adrenergic stimulation with isoproterenol and high glucose compared to their non-dia

62 ciation-6 (INCA6) prevented IKs reduction by isoproterenol and INCA6 suppressed isoproterenol-induced

63 oduced in the presence of the betaAR agonist isoproterenol and intracellular calcium.

64 imal response elicited by the betaAR agonist isoproterenol and its potency in a cAMP accumulation ass

65 ound that the phosphorylation of PREX1 after isoproterenol and prostaglandin E2-mediated GPCR activat

66 Compared with baseline in AF patients, isoproterenol and rapid pacing decreased activation late

67 amically diverse beta-adrenoceptor agonists, isoproterenol and salmeterol.

68 Although isoproterenol and stepwise increases in stimulation freq

69 The beta-adrenergic stimulation (isoproterenol) and antagonist trials (verapamil) address

70 n the presence or absence of propranolol and isoproterenol) and defined pathways that were perturbed

71 ria expression in osteoblasts, regulation by isoproterenol, and ability to trap the insulin receptor

72 ylcholinesterase (AChE) with metaproterenol, isoproterenol, and newly synthesized racemic bisdimethyl

73 the SR induced by a beta-adrenergic agonist, isoproterenol, and subsequently blocks isoproterenol-ind

74 affinity catecholamine agonist hydroxybenzyl isoproterenol, and the low-affinity endogenous agonist a

75 bited arrhythmic contractions in response to isoproterenol, and up to 20% of STAA cells failed to sus

76 larly, Epac1 KO animals showed resistance to isoproterenol- and aging-induced cardiomyopathy and atte

77 Using the beta-adrenergic agonist isoproterenol as a specific pathological stressor to cir

78 Plasma levels of isoproterenol at each increment were measured by liquid

79 duced MCCV-increases induced by forskolin or isoproterenol but not increases induced by carbachol.

80 nduced by Angiotensin II, phenylephrine, and isoproterenol, but did not affect cardiac myocyte physio

81 nse to 10 muM of the beta-adrenergic agonist isoproterenol (by 42%), 10 muM of the adenyl cyclase act

82 Accordingly, in the presence of isoproterenol, Ca(2+) transients and contraction amplitu

83 found that treatment with the beta-AR agent isoproterenol caused substantial LD loss via activation

84 all Ca(2+)-sensitized hearts, in vivo after isoproterenol challenge and in isolated hearts after rap

85 We used pressure-volume relationships and isoproterenol challenge to assess the effect of recombin

86 e of recurrent arrhythmia >1 year, high-dose isoproterenol challenge was used to disclose non-PV trig

87 Isoproterenol challenge yielded additional 36.4% of thos

88 ency and dimensions in cardiomyocytes during isoproterenol challenge, and reduced the incidence of Ca

89 curred in only 7/150 PVs (4.7%) on adenosine/isoproterenol challenge.

90 Electrocardiography on isoproterenol challenged mice showed that both models de

91 fibrosis and inflammation in aged as well as isoproterenol-challenged heart than age-matched wild typ

92 on at 90% repolarization and after 10 nmol/L isoproterenol compared with WT (n=7; P<0.05).

93 e hearts at ZT14 had diminished responses to isoproterenol compared with ZT4 (ZT4: 49.5.0+/-5.6% vers

94 he beta-adrenergic receptor (betaAR) agonist isoproterenol, consistent with the immunoelectron micros

95 Unlike isoproterenol, CXL-1020 was equally effective in myocyte

96 armacological inhibition of MMP-13 prevented isoproterenol-dependent cardiac dysfunction in mice.

97 This isoproterenol-dependent cleavage was significantly reduc

98 ury induced by one or multiple high doses of isoproterenol, despite expressing ~57% dystrophin.

99 Oxidative stress induced by chronic isoproterenol, detected by 8-OhDG was 15% greater, P=0.0

100 neural influences on heart rate (HR) during isoproterenol, dexmedetomidine and glycopyrrolate were g

101 4(-/-) mice with the beta-adrenergic agonist isoproterenol did not trigger ventricular arrhythmia but

102 cle strips from Tg-CTGF mice stimulated with isoproterenol displayed attenuation of maximal inotropic

103 Isoproterenol doses were increased incrementally until H

104 Isoproterenol dramatically increased the frequency of Ca

105 (EC50 1.8 mM) and verapamil (IC50 0.61 muM); isoproterenol elicited a positive chronotropic but negli

106 Isoproterenol elicited dose-dependent increases in cardi

107 tion with the inotropic and lusitropic agent isoproterenol eliminated the differences among wild-type

108 induction by programmed stimulation without isoproterenol, entrainment in some, and abnormal electro

109 that the Galpha(s)-coupled receptor agonists isoproterenol, epinephrine, norepinephrine, prostaglandi

110 cells, yielded a wider release source in the isoproterenol event, indicating the recruitment of perip

111 1C myocytes from older mice are treated with isoproterenol, evidence of excitation-contraction uncoup

112 port that stimulation of cardiomyocytes with isoproterenol, evokes dynamic, protein kinase A-dependen

113 osteoclast hyperfunction while beta-agonist (isoproterenol) exacerbated those responses.

114 Sustained isoproterenol exposure decreased IKs density (whole cell

115 ecreased IKs density to an extent similar to isoproterenol exposure, and adenoviral-mediated knockdow

116 A inhibitor peptide transgenic mice, chronic isoproterenol failed to induce cardiac hypertrophy, fibr

117 ulation of HFpEF myocytes with isoprenaline (isoproterenol) failed to elicit robust increases in I(Ca

118 In cardiac-specific Bin1 heterozygote mice, isoproterenol fails to concentrate BIN1 to t-tubules, im

119 ive isoproterenol group than in the negative isoproterenol group (P<0.0001, exact log-rank test).

120 osis was significantly lower in the positive isoproterenol group than in the negative isoproterenol g

121 culture with or without IL-13 (48 hours) or isoproterenol hydrochloride (ISO; 30 minutes) pretreatme

122 mained unchanged, and activation of PKA with isoproterenol improved cardiac contractility.

123 n determined the electrophoretic mobility of isoproterenol in a high ion solution to be -7 x 10(-9) m

124 amined the cardiomyopathy induced by chronic isoproterenol in AC5 transgenic (Tg) mice and the signal

125 SR Ca(2+) content and SANC rate responses to isoproterenol in mice with AC3-I expression, suggesting

126 mpanying action potentials were increased by isoproterenol in myocytes from WT mice, but these effect

127 e variability and fractal behavior, and that isoproterenol increased and carbamylcholine decreased th

128 Chronic isoproterenol increased oxidative stress and induced mor

129 Isoproterenol increases (+57%) and acetylcholine decreas

130 mulation of wild-type EPCs with beta-agonist isoproterenol induced a significant increase of Flk-1 ex

131 Accordingly, SN attenuated isoproterenol induced autophosphorylation of Thr287-CaMK

132 Interestingly, isoproterenol induced CD36 internalization, and this pro

133 Isoproterenol induced global decreases in methylation in

134 e, we found that the beta-adrenergic agonist isoproterenol induced mature beta-adrenergic signaling i

135 Isoproterenol induced nuclear NFATc3/c4 translocation (i

136 lphas-coupled beta-adrenergic receptors with isoproterenol induced PKA-dependent activation of endoge

137 ly, proximity ligation assays indicated that isoproterenol induced PKA-dependent phosphorylation of e

138 , NAADP antagonist BZ194 largely ameliorated isoproterenol-induced arrhythmias in awake mice.

139 CD38 in docking simulations and reduced the isoproterenol-induced arrhythmias in WT hearts.

140 ion of intracellular calcium homeostasis and isoproterenol-induced arrhythmias that are prevented by

141 on of Cx43 immunosignals, protection against isoproterenol-induced arrhythmias, and improved Ca2+ hom

142 ed marked defects in both PKA activation and isoproterenol-induced ATGL translocation to the LD perip

143 nd DAD-induced triggered activity as well as isoproterenol-induced automaticity elicited in SVC sleev

144 n of Abcc6 dramatically and rapidly promotes isoproterenol-induced cardiac fibrosis.

145 exhaustive exercises and less susceptible to isoproterenol-induced cardiac hypertrophy at both young

146 fied an inhibitory effect of UDP on in vitro isoproterenol-induced cardiomyocyte hyperplasia and hype

147 differentiation stimuli, sensitizing CPC to isoproterenol-induced cell death that is abrogated by me

148 ore, AAV9-miRYR2-U10 effectively (1) reduced isoproterenol-induced delayed afterdepolarizations and t

149 f mice that are susceptible and resistant to isoproterenol-induced dysfunction to test the hypothesis

150 Finally, isoproterenol-induced GRK2 phosphorylation enhanced CAV1

151 etermined to be susceptible and resistant to isoproterenol-induced heart failure, respectively, were

152 In the isoproterenol-induced hypertrophic mouse model, we show

153 wed an impaired capacity to adapt to stress (isoproterenol-induced hypertrophy), likely because of de

154 panol dihydrochloride (CGP-20712A) prevented isoproterenol-induced IKs downregulation, whereas the be

155 oviral-mediated knockdown of Epac1 prevented isoproterenol-induced IKs/KCNE1 downregulation.

156 mal function with bafilomycin A1 reduced the isoproterenol-induced increase in Ca(2+) transients in c

157 P) of synaptic vesicles, consistent with the isoproterenol-induced increase in vesicle docking in cer

158 soproterenol, a beta-adrenergic agonist, and isoproterenol-induced increases in the NFAT target genes

159 KO myocytes display decreased sensitivity to isoproterenol-induced induction of arrhythmogenic I(Na,L

160 uction by isoproterenol and INCA6 suppressed isoproterenol-induced KCNE1 downregulation, consistent w

161 eta-adrenergic signaling and is required for isoproterenol-induced myocardial hypertrophy.

162 nist, isoproterenol, and subsequently blocks isoproterenol-induced PKA phosphorylation of phospholamb

163 the Kv7 inhibitor linopirdine, and impaired isoproterenol-induced relaxations.

164 Isoproterenol-induced stress or cyclic strain demonstrat

165 cholinergic stimulation completely abolished isoproterenol-induced triggered activity in both dyssync

166 and release, consistent with the absence of isoproterenol-induced ventricular arrhythmia.

167 ling in response to 2 independent stressors: isoproterenol infusion and an activated calcineurin tran

168 ntrols underwent exercise testing and graded isoproterenol infusion to quantify cardiac beta-receptor

169 subjected to pressure overload stimulation, isoproterenol infusion, and swimming showed greater card

170 subjected to thoracic aortic constriction or isoproterenol infusion.

171 PVCs in all the VTs induced during high-dose isoproterenol infusion.

172 of which 16 (59%) occurred during high-dose isoproterenol infusion.

173 e attenuating hypertrophy induced by chronic isoproterenol infusion.

174 d by transverse aortic constriction (TAC) or isoproterenol infusion.

175 Isoproterenol infusions induced anxiety in both patients

176 is recognized using pacing maneuvers and/or isoproterenol infusions.

177 SAN automaticity in RyR2(R4496C) mice after isoproterenol injection, analogous to what was observed

178 taneously as assessed by ECG telemetry after isoproterenol injection.

179 thological cardiac hypertrophy induced after isoproterenol injection.

180 p sequencing in mouse hearts after 7 days of isoproterenol injections (3 mg.kg(-1).mg(-1)), transvers

181 Here, we applied isoproterenol into these surface openings by changing th

182 myocytes stimulated with the beta-AR agonist isoproterenol (ISO) (anxA4a(+/+) vs. anxA4a(-/-): 5.1 +/

183 centrations of the beta-adrenoceptor agonist isoproterenol (ISO) and by varying afterload pressures.

184 We report that isoproterenol (ISO) and related beta2-adrenergic agonist

185 served that chronic beta-AR stimulation with isoproterenol (ISO) for 48 h reduced Ito,f along with mR

186 sceptibility of cardiac damage responding to isoproterenol (ISO) in adult offspring that underwent ma

187 Isoproterenol (ISO) increased Ca2+ transient amplitude d

188 uced in wild-type and IL-10 knockout mice by isoproterenol (ISO) infusion.

189 The effects of the PKA activator Isoproterenol (Iso) on L-type Ca(2+) current (I(CaL)), c

190 compare myocardial remodeling in response to isoproterenol (Iso) or Angiotensin II (Ang II).

191 Isoproterenol (ISO) or PKA activation results in strong

192 Here, we show that chronic administration of isoproterenol (ISO) persistently increases the frequency

193 stimulation of beta-adrenergic receptors by isoproterenol (ISO) resulted in an impaired contractile

194 duration (APD(80)) between groups; however, isoproterenol (ISO) significantly shortened APD(80) in D

195 es measured under basal conditions and after isoproterenol (Iso) stimulation.

196 eta-adrenergic receptor stimulation (through isoproterenol (ISO) treatment) on heart metabolism.

197 lar ejection fraction after stimulation with isoproterenol (ISO), a beta-adrenergic receptor (betaAR)

198 ) followed by the beta-adrenoceptor agonist, isoproterenol (ISO), or the beta-adrenoceptor antagonist

199 to multiple hypertrophic stimuli, including isoproterenol (ISO), phenylephrine (PE), and endothelin-

200 experiments reveal that the betaAR agonist, isoproterenol (ISO), promotes enhanced Ca(V) 1.2-Ca(V) 1

201 ilator-stimulated phosphoprotein (p-VASP) by isoproterenol (ISO), prostaglandin E(2) (PGE(2)), or for

202 r, or genetic inhibition by siRNA to Ces3 on isoproterenol (ISO)-treated 3T3-L1 and brown adipocyte c

203 with high glucose (HG) and the beta-agonist isoproterenol (ISO).

204 The beta-adrenergic agonist isoproterenol (ISO; 1 muM) increased [Ca(2+)](SR) well a

205 ated that a single subcutaneous injection of isoproterenol (ISO; 200 mg/kg) in mice causes acute myoc

206 ization (BVR) during adrenergic stimulation (isoproterenol, ISO).

207 derivatives of metaproterenol (metacarb) and isoproterenol (isocarb) and their (R)-enantiomers to see

208 itions: (1) beta-adrenergic stimulation with isoproterenol (isoprenaline) accelerated spark amplitude

209 itions: (1) beta-adrenergic stimulation with isoproterenol (isoprenaline) accelerated spark amplitude

210 ild-type mice with the beta-receptor agonist isoproterenol (isoprenaline) increased RyR1 PKA phosphor

211 t was combined with a cAMP-mediated agonist (isoproterenol (isoprenaline) or vasoactive intestinal pe

212 young postnatal cardiomyocytes responded to isoproterenol (isoprenaline) with a decrease in cell siz

213 vity (beta-adrenergic stimulation with 1 muM isoproterenol (isoprenaline)) decreased the latency peri

214 e regions during adrenergic stimulation with isoproterenol (isoprenaline; ISO).

215 However, in the presence of isoproterenol, leak produced a biphasic decay of the Ca

216 Exposure to isoproterenol led to phosphorylation of PDE3A1 at the 14

217 ed I(K1) IV relationship; however, following isoproterenol, max outward I(K1) increased by ~20% in WT

218 This reduced response to isoproterenol may be attributable to the lower cAMP sens

219 These findings suggest that dopamine and isoproterenol may enhance CRF release from local BNST so

220 quent rescue by isoproterenol and additional isoproterenol-mediated desensitization.

221 Moreover, isoproterenol-mediated increase in contraction rate, sur

222 o increased PDE4D expression causing reduced isoproterenol-mediated phosphorylation of cTnI and PLN.

223 Isoproterenol (n=14), adenosine (n=10), or rapid pacing

224 0.133 versus 0.254+/-0.166 beats per minute/[isoproterenol ng/mL]; P<0.001).

225 vivo incubation of mouse kidney slices with isoproterenol, norepinephrine, and parathyroid hormone s

226 de enhanced the effect of the bronchodilator isoproterenol on airway relaxation.

227 release, abolishes the inhibitory effect of isoproterenol on histamine-induced intracellular calcium

228 The effects of isoproterenol on relaxation velocity, left ventricular s

229 PKA inhibitor Rp-cAMPS blocks the effects of isoproterenol on the nuclear influx of HDAC4-GFP, and Rp

230 During beta-adrenergic stimulation (100 nM isoproterenol), only Casq2(-/-) atrial myocytes showed p

231 tivation of PKA by the beta-receptor agonist isoproterenol or dibutyryl (Db) cAMP causes a steady HDA

232 n of hormone sensitive lipase in response to isoproterenol or forskolin.

233 arget sites failed to affect HR responses to isoproterenol or spontaneous activity in vivo or in SANC

234 ate and SAN cell automaticity in response to isoproterenol or the dihydropyridine Ca(2+) channel agon

235 t failure was induced by 2 weeks infusion of isoproterenol or transverse aortic constriction.

236 agonizing the smooth muscle contraction with isoproterenol, or by blocking myosin light chain kinase

237 (2+)-mediated EADs and focal activity during isoproterenol perfusion (at 30 nmol/L, n=7/12 and 100 nm

238 s which distinctly regulate cell response to isoproterenol, phenylephrine, angiotensin II and stretch

239 ion of these receptors through their agonist isoproterenol potentiated synaptic transmission in cereb

240 n contrast, we show that when application of isoproterenol precedes application of NMDA by several mi

241 rs exposed to the LTCC agonists BayK8644 and isoproterenol produce EAD bursts that are suppressed by

242 Isoproterenol redistributes BIN1 to t-tubules, recruitin

243 mplitude of L-type Ca(2+) currents evoked by isoproterenol remained unchanged in myocytes from Tpcn2(

244 Using an isoproterenol rescue protocol after either short-term (1

245 n of LQT2 cells with beta-adrenergic agonist isoproterenol resulted in prolongation of the plateau of

246 e subjected to chronic exposure (14 days) to isoproterenol revealed blunted myocardial hypertrophy an

247 y and Western blotting, we demonstrated that isoproterenol, S-propranolol, CGP-12177 [4-[3-[(1,1-dime

248 ry vein triggers disclosed by high dosage of isoproterenol seems to be of utmost importance to achiev

249 from Tpcn2(-/-) mice chronically exposed to isoproterenol showed less cardiac hypertrophy and increa

250 isolated from CD38(-/-) mice and exposed to isoproterenol showed reduced arrhythmias.

251 21C mice demonstrate that in the presence of isoproterenol, significant delays in Ca(2+) decay and sa

252 is approach, we found that both dopamine and isoproterenol significantly depolarized BNST CRF neurons

253 Computational modeling revealed that isoproterenol steepened APD restitution by increased L-t

254 proliferation increased in diabetic animals: isoproterenol stimulated SGLT1 migration to luminal memb

255 Concentration-response curves of isoproterenol-stimulated cAMP generation in cardiomyocyt

256 CST did not affect basal or isoproterenol-stimulated cAMP production in adipocytes b

257 RVMs stimulated with conditioned medium from isoproterenol-stimulated cardiac fibroblasts.

258 ere more frequent and had shorter latency in isoproterenol-stimulated cardiomyocytes from RyR2-V2475F

259 ol and Ncx1(-/-) SAN cells under resting and isoproterenol-stimulated conditions.

260 ive AC9 in neonatal cardiomyocytes decreases isoproterenol-stimulated Hsp20 phosphorylation, consiste

261 mediated glucose uptake, increased basal and isoproterenol-stimulated lipolysis, and decreased adipoc

262 S660, increasing its hydrolase activity and isoproterenol-stimulated lipolysis.

263 reased alkaline phosphatase-PAR1 cleavage in isoproterenol-stimulated NRVMs, as well as in NRVMs stim

264 In isoproterenol-stimulated ventricular myocytes, the RyR2-

265 onditions (DeltaISC 7.1 muA/cm(2)) and after isoproterenol stimulation (increased DeltaISC from 13.9

266 of spontaneous contractions upon adrenergic isoproterenol stimulation and nearly abolished ryanodine

267 ound that salmeterol progressively depressed isoproterenol stimulation but did not prevent subsequent

268 Isoproterenol stimulation reversed the depressive contra

269 Two-week isoproterenol stimulation showed an increase in heart gr

270 in vivo muscle strength responses following isoproterenol stimulation were abrogated in RyR1-S2844A

271 effectively than in control SAN cells after isoproterenol, suggesting that the importance of NCX cur

272 Ventricular arrhythmogenicity during isoproterenol testing is highly sensitive (sensitivity,

273 positive, and negative predictive values of isoproterenol testing to diagnose ARVC were 91.4%, 88.9%

274 Isoproterenol testing was performed with continuous infu

275 Isoproterenol testing was positive in 32 of 35 (91.4%) p

276 Importantly, initial isoproterenol testing was positive in 6 of 6 (100%) of t

277 2-lead ECG recordings at baseline and during isoproterenol testing.

278 to the CA1, the beta-adrenoreceptor agonist, isoproterenol, the D1/D5 dopaminergic receptor antagonis

279 had an arrhythmic death when stimulated with isoproterenol; the lethal arrhythmias were rescued, in p

280 cultured 3T3-L1 adipocytes were treated with isoproterenol to activate lipolysis and the fatty acyl l

281 n inhibits the ability of the betaAR agonist isoproterenol to enhance hippocampal LTP, and this effec

282 Chronic in vivo administration of isoproterenol to guinea pigs reduced IKs density and KCN

283 rats were intranasally treated with saline, isoproterenol (to increase SGLT1 activity) or phlorizin

284 myocytes (NRVMs) or cardiac fibroblasts with isoproterenol transduced with an alkaline phosphatase-ta

285 reduces cardiac fibrosis (~50% reduction) in isoproterenol-, transverse aortic constriction-, and myo

286 In isoproterenol-treated DBA/2 mice, there was also a great

287 ypertensive rats and antifibrotic effects in isoproterenol-treated rats.

288 ity and the greater spark width found during isoproterenol treatment may increase the probability of

289 It was found that isoproterenol treatment shifts the spark-frequency-J(lea

290 congestion, and fibrosis induced by chronic isoproterenol treatment.

291 e basal state between strains and then after isoproterenol treatment.

292 sue (BAT) and is further induced by cold and isoproterenol treatments of BAT and primary brown adipoc

293 dition, the incremental increase elicited by isoproterenol was abolished in neonatal cardiomyocytes a

294 shift of the If activation curve induced by isoproterenol was attenuated in pregnancy.

295 increase in L-type Ca(2+) current caused by isoproterenol was markedly reduced at physiological leve

296 esence of a beta-adrenergic receptor agonist isoproterenol, was significantly higher in VF myocytes t

297 These metabolic changes induced by isoproterenol were associated with increased sarcoplasmi

298 in RyR2(R4496C) SAN cells in the presence of isoproterenol, which may contribute to stopping the "Ca(

299 tion response to the beta-adrenergic agonist isoproterenol, without affecting endothelin-induced vaso

300 splayed poor affinity for metaproterenol and isoproterenol, yet BChE(UU) had an affinity about five t